Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Riociguat (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Bayer
- 15 Mar 2017 Planned End Date changed from 1 Jan 2018 to 31 Jan 2018.
- 15 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 17 Jan 2018.
- 13 Sep 2016 Number of treatment arms changed from 2 to 4.